GSK Presents New Research in Pulmonology at ERS Congress

GlaxoSmithKline (GSK) will present over 60 research papers at the European Respiratory Society Congress. The data focuses on depemokimab, an experimental antibody for severe asthma, and mepolizumab, used in several diseases, with new analyses in COPD patients. The company will also share advances in inhaled treatments and its RSV vaccine in young adults at risk.

GlaxoSmithKline (GSK) will present over 60 research papers at the upcoming European Respiratory Society (ERS) Congress 2025, scheduled from September 27 to October 1 in Amsterdam, the Netherlands. The presentations will cover a wide range of respiratory diseases, including asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), chronic obstructive pulmonary disease (COPD), and infectious respiratory diseases. The research focuses on GSK's portfolio of biologics and inhaled therapeutics, aiming to advance the science surrounding these conditions.

One of the key highlights is the presentation of data on depemokimab, an investigational ultra-long-acting monoclonal antibody, which is being studied in patients with severe asthma and comorbid CRSwNP. The company will share results from the Phase III SWIFT-1 and SWIFT-2 trials, exploring different groups of asthma patients who could benefit from depemokimab, including those with comorbid CRSwNP and those requiring medium- or high-dose inhaled corticosteroids (ICS) at baseline GSK to showcase new research from its broad respiratory portfolio at the European Respiratory Society (ERS) Congress 2025^[1].

GSK will also present new analyses from the Phase III trials of mepolizumab in COPD, including an indirect treatment comparison from the MATINEE trial, which will contextualize the results compared to another approved COPD biologic. The analysis focuses on the risk of exacerbation and the change in Saint George's Respiratory Questionnaire (SGRQ) in patient groups examined in other COPD biologic trials .

Additionally, GSK will share data on its RSV vaccine in younger adults at risk of illness and infection due to certain underlying conditions. A post-hoc analysis of the pivotal AReSVi-006 trial will also be presented, evaluating the efficacy in adults with asthma and COPD, including the impact on exacerbations and the use of corticosteroids and antibiotics .

The presentations will also cover various aspects of GSK's portfolio of inhaled therapeutics, including fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and salbutamol metered-dose inhaler (MDI) with a low global warming potential propellant. Several of these presentations reflect ongoing research into the earlier use of maintenance therapies, efforts to support symptom control and reduce the risk of exacerbations, while others explore sustainable approaches to asthma and COPD management .

The ERS Congress 2025 will provide a platform for GSK to showcase its commitment to advancing respiratory research and improving patient outcomes.